The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

So, and it is nice to speak about gynecologic cancers, as we know, endometrial cancer was and still is the most common ... second line was Vicki Makker and her colleagues put pembrolizumab and ...

827 patients with advanced endometrial cancer who had progressive disease after platinum-based chemotherapy were randomly assigned to receive lenvatinib plus pembrolizumab (411 patients ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Keytruda (pembrolizumab) is a prescription drug ... Keytruda may be prescribed by itself or with chemotherapy in this case. Endometrial cancer: Keytruda is used for endometrial cancer that meets ...

Peers & Perspectives in Oncology: What options do the National Comprehensive Cancer Network (NCCN ... Cabozantinib plus nivolumab [Opdivo] and lenvatinib [Lenvima] plus pembrolizumab [Keytruda] are ...

Meanwhile, rival PD-1 inhibitor Keytruda (pembrolizumab ... has already been approved in other indications including endometrial cancer. Merck forged a $5.76 billion collaboration for Eisai ...

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 ...